Enrico Cortesi

Pubblicazioni

Titolo Pubblicato in Anno
Transient disappearance of RAS mutant clones in plasma: A counterintuitive clinical use of EGFR inhibitors in RAS mutant metastatic colorectal cancer CANCERS 2019
Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial THE ONCOLOGIST 2019
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience JOURNAL OF CELLULAR PHYSIOLOGY 2019
No evidence of association between psychological distress and pain relief in patients with bone metastases from castration‐resistant prostate cancer treated with 223Radium EUROPEAN JOURNAL OF CANCER CARE 2019
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer LUNG CANCER 2019
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme BJU INTERNATIONAL 2019
Cabozantinib in renal cell carcinoma with brain metastases: safety and efficacy in a real-world population CLINICAL GENITOURINARY CANCER 2019
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting INTERNATIONAL JOURNAL OF CANCER 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program JOURNAL FOR IMMUNOTHERAPY OF CANCER 2019
Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer FRONTIERS IN ONCOLOGY 2019
Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor? CLINICAL ENDOCRINOLOGY 2019
Incidence of portal hypertension in patients exposed to oxaliplatin DIGESTIVE AND LIVER DISEASE 2019
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer EUROPEAN JOURNAL OF CANCER 2019
Italian cohort of Nivolumab expanded access program in squamous non-small cell lung cancer: results from a real-world population THE ONCOLOGIST 2019
Adjuvant chemotherapy in resected colon cancer: when, how and how long? SURGICAL ONCOLOGY 2019
Adoption and application in Italy of the principal guidelines and international recommendations on venous access MINERVA MEDICA 2018
EGFR inhibitor as second-line therapy in a patient with mutant RAS metastatic colorectal cancer: circulating tumor DNA to personalize treatment JCO PRECISION ONCOLOGY 2018
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO ANNALS OF ONCOLOGY 2018
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer ONCOTARGET 2018
Relationship and predictive role of the dual expression of FGFR and IL-8 in metastatic renal cell carcinoma treated with targeted agents ANTICANCER RESEARCH 2018

Progetti di Ricerca

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma